1. ICH M7(R1) on
assessment and control of DNA reactive (mutagenic)
impurities in pharmaceuticals to limit potential carcinogenic risk. EMA/CHMP/ICH/83812/2013. European Medicines Agency, August 25, 2015. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m7r1-assessment-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit_en.pdf (accessed 2020-07-03).
2. OECD Guideline for Testing
of Chemicals. No. 471: Bacterial Reverse
Mutation Assay. Organisation for Economic Co-operation and
Development (OECD), July 21, 1997. https://www.oecd.org/chemicalsafety/risk-assessment/1948418.pdf (accessed 2020-08-27).
3. The Bacterial Reverse Mutation Test
4. A comparison of Derek and Sarah Nexus.
Lhasa Limited, UK, 2017. https://www.lhasalimited.org/Public/Library/2017/A%20comparison%20of%20Derek%20and%20Sarah%20Nexus.pdf (accessed 2020-07-03).
5. Leadscope Model Applier
and the ICH M7 Impurities Guidelines. Leadscope, Inc., June 2016. https://www.leadscope.com/faq/LSMA-ICHM7-FAQs-June2016.pdf (accessed
2020-07-03).